The company’s stock, currently trading at $529.24 ... Eylea has been a significant revenue driver for Regeneron, and its decline poses a substantial risk to the company’s financial performance.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.11, a high estimate of $68.00, ...

The S&P 500 added 0.6% on Tuesday, June 10, 2025, as investors awaited developments in the trade negotiations between the U.S ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

The stock's fall snapped a two-day winning streak.

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN. Shivank Goswami Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

Regeneron Pharmaceuticals took a modest hit as BDF Gestion reduced its stake by 11.5% in the first quarter, now holding $2.8 ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...